News | July 24, 2007

Scientists Pinpoint Genes Likely to Cause CAD

July 25, 2007 - Researchers have confirmed that six new genetic variants increase the likelihood of developing coronary artery disease (CAD), according to a study by the University of Leicester and the University of Leeds, UK, and the Universities of Lubeck and Regensburg, Germnay, published by the journal New England Journal of Medicine.

The study, part of the Wellcome Trust Case Control Consortium (WTCCC) and the largest study to date of the genetics of common disease, involved a genome-wide analysis conducted on 2,000 participants with CAD and 3,000 healthy controls as. The findings were then compared with the German MI Family Study, with almost 900 addition cases and 1600 additional controls.

The study showed that changes in our DNA on chromosomes 2, 6, 10 and 15 and two on chromosome 1 were associated with increased risk of developing CAD and heart attacks. Researchers also confirmed the importance of a variant on chromosome 9.

For more information: www.wellcome.ac.uk

Related Content

The Corus CAD genetic test is a simple, noninvasive blood test that is clinically available for the assessment of obstructive coronary artery disease.

The Corus CAD gene expression test is a simple, noninvasive blood test that is available to assess a patient’s current likelihood of having obstructive coronary artery disease (CAD).

 

Feature | Genetic Testing | December 13, 2017 | Andrew Waxler, M.D., FACC
The diagnosis and management of cardiovascular disease has long followed a familiar approach.
genetic testing, sudden cardiac death of teen, Mayo Clinic Proceedings
News | Genetic Testing | November 09, 2016
The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having...
News | Genetic Testing | July 26, 2016
July 26, 2016 — A new study has identified a genetic error that weakens the aorta, placing patients with this and sim
Feature | Genetic Testing | December 22, 2015 | Kevin P. Greene, M.D.
Statins are lifesaving medications — they have been shown to greatly reduce heart attack and other related events by
Invitae Corp., cardiovascular test panels, genetic testing, expands offerings
Technology | Genetic Testing | October 08, 2015
Invitae Corp., a genetic information company, announced the expansion of its cardiology offering, including more than...
genomic testing, NGS, FDA, Precision Medicine Initiative, PMI, workshops
Feature | Genetic Testing | September 21, 2015
The U.S. Food and Drug Administration (FDA) will hold a pair of public workshops in November to explain ongoing efforts...
Overlay Init